Genus plc (LON:GNS)
2,665.00
-10.00 (-0.37%)
At close: Mar 18, 2026
Genus Revenue
Genus had revenue of 335.60M GBP in the half year ending December 31, 2025, with 0.60% growth. This brings the company's revenue in the last twelve months to 672.00M, up 0.06% year-over-year. In the fiscal year ending June 30, 2025, Genus had annual revenue of 672.80M with 0.60% growth.
Revenue (ttm)
672.00M
Revenue Growth
+0.06%
P/S Ratio
2.65
Revenue / Employee
210.66K
Employees
3,190
Market Cap
1.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 672.80M | 4.00M | 0.60% |
| Jun 30, 2024 | 668.80M | -20.90M | -3.03% |
| Jun 30, 2023 | 689.70M | 96.30M | 16.23% |
| Jun 30, 2022 | 593.40M | 19.10M | 3.33% |
| Jun 30, 2021 | 574.30M | 22.90M | 4.15% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oxford Nanopore Technologies | 223.90M |
| Oxford Biomedica | 151.21M |
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
Genus News
- 16 days ago - Genus Power Surpasses 26 Million Smart Meter Deployment Worldwide, Reinforcing Leadership in End-to-End Advanced Metering Solutions - PRNewsWire
- 20 days ago - Genus plc (GENSY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - UK animal genetics firm Genus surges on annual profit forecast upgrade - Reuters
- 6 months ago - Genus Plc (GENSY) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 6 months ago - British animal genetics firm Genus surges on strong annual profit growth - Reuters
- 11 months ago - UK's Genus secures FDA approval for PRP gene edit; shares soar - Reuters
- 1 year ago - Genus plc (GENSF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Genus plc (GENSF) Q3 2024 Earnings Call Transcript - Seeking Alpha